- Oops!Something went wrong.Please try again later.
Dianne Whitfield joins Tarsus as CHRO
IRVINE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, today announced the appointment of Dianne Whitfield to the position of Chief Human Resources (HR) Officer. Ms. Whitfield has more than 20 years of experience in human resources, including over a decade of management and leadership experiences in the life sciences industry.
Most recently, Ms. Whitfield served as Vice President and Head of Human Resources for Evolus, Inc., where she led efforts to support the commercialization of the startup company’s first approved product. While at Evolus, she designed strategy and executed programs focused on recruiting top talent and building a positive culture and an effective employee experience, to drive engagement and business results.
“Dianne’s appointment to the position of Chief HR Officer comes at an incredibly exciting time for our business, as we lay the foundation for long-term organizational growth,” said Bobak Azamian, MD, PhD, CEO, Tarsus Pharmaceuticals, Inc. “Dianne brings a wealth of leadership experience, including her recent tenure at Evolus, where she built a talented, multifunctional team in a growing startup, defined an engaging culture, and supported the launch of a new pharmaceutical product. We look forward to Dianne’s leadership as we continue to build the Tarsus team and a culture that will best enable our company’s mission.”
Prior to Evolus, Ms. Whitfield held positions of increasing responsibility at Allergan (an AbbVie company) where she progressed to the role of Director of Global Human Resources. Her experience there spanned a variety of human resources business partnership and leadership roles where she supported both the Commercial and Research & Development organizations and led enterprise-wide initiatives in Global Talent Management. She has broad experience building organizations and supporting product launches in multiple therapeutic areas including eye care, as well as expertise in developing culture and talent programs to drive organizational success. Dianne holds a Bachelor of Arts in Psychology and Social Behavior from the University of California, Irvine and a Masters in Social Work from California State University, Long Beach.
“I’m thrilled to join the experienced and talented management team at Tarsus, and look forward to driving its next phase of growth by curating a differentiated culture that captures the Tarsus spirit of innovation, and enables talent to achieve our mission,” said Ms. Whitfield.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding future events and Tarsus’ plans for and the anticipated benefits of its product candidates, the timing, objectives and results of the clinical studies and anticipated regulatory and development milestones. The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will” or “would” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, and are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus’ management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Pascale Communications, LLC
Westwicke Partners, an ICR company
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5be39cb4-2eac-49dc-9d36-4eedaaca35c9